Instituto DOr de Pesquisa e Ensino

São Paulo 04543 000

2 studies enrolling now · 8 studies all time

What they study most

Breast Cancer, Colitis, Ulcerative, Follicular Lymphoma, Leukemia, Myeloid, Acute, Multiple Myeloma, Post-Essential Thrombocythemia MF (Post-ET-MF), Post-Polycythemia Vera MF (Post-PV-MF), Primary Myelofibrosis (PMF), Refractory Follicular Lymphoma, Relapsed Refractory Multiple Myeloma (RRMM), Relapsed/Refractory Follicular Lymphoma

Studies at this site

• A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) — Recruiting now
• A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma — Recruiting now
• A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide — Running, not enrolling
• A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. — Running, not enrolling
• A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• The OPBC-07/microNAC Study — Running, not enrolling
• KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment — Status unconfirmed